Evidence map›Paper›PMID 41249505›Full record

ArticleThe EMBO journal2025

Measuring mitochondrial membrane potential.

Oscar Tovar-Ferrero, Javier Rubio, Antonio Zorzano, Guillermo Martínez-Corrales, Marc Liesa

Abstract read
In one paragraph

Article in The EMBO journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Oscar Tovar-Ferrero *Institut de Biologia Molecular de Barcelona, IBMB, CSIC, C/Baldiri Reixac 10, Barcelona, 08028, Catalonia, Spain.ORCID http://orcid.org/0009-0005-6959-7460
Javier Rubio *Institut de Biologia Molecular de Barcelona, IBMB, CSIC, C/Baldiri Reixac 10, Barcelona, 08028, Catalonia, Spain.ORCID http://orcid.org/0000-0003-0320-5100
Antonio ZorzanoCIBERDEM, Instituto de Salud Carlos III, Madrid, Spain.ORCID http://orcid.org/0000-0002-1638-0306
Guillermo Martínez-CorralesInstitut de Biologia Molecular de Barcelona, IBMB, CSIC, C/Baldiri Reixac 10, Barcelona, 08028, Catalonia, Spain. gmcbmc@ibmb.csic.es.ORCID http://orcid.org/0000-0002-3923-5902
Marc LiesaInstitut de Biologia Molecular de Barcelona, IBMB, CSIC, C/Baldiri Reixac 10, Barcelona, 08028, Catalonia, Spain. mlrbmc@ibmb.csic.es.ORCID http://orcid.org/0000-0002-5909-8570

Funding

BBVA | Fundación BBVA (FBBVA) LEO22-2-1659-BBM-BIO-18.Consejo Superior de Investigaciones Científicas (CSIC) Scientific Network Enfermedades MetabólicasMinisterio de Ciencia e Innovación (MCIN) PID2021-127278NB-I00Ministerio de Ciencia e Innovación (MCIN) PID2023-146293NA-I00
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41249505
PMCPMC12706018

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.